Canadian Cancer Trials Group - Tumour Bank
Logged in as: Public
Location: Home - Disease Sites - - I170
I170 Details
Status: Closed 
Activation Date: 2004DEC16
Closing Date: 2007MAY08
Phase: I-II 

Description: A Phase I/II Study of GW572016 in Patients With Recurrent Malignant Glioma 

Eligibility: Patients with recurrent glioblastoma multiforme (GBM) following primary surgery and radiation. No prior chemotherapy for recurrent disease permitted. Bidimensionally measureable disease. Stable dose of steriods. Paraffin embedded tumour sample available for study. 

Objective: To determine the toxicity, MAD, and RPII dose of GW572016 when given in patients with GBM taking CYP3A4 enzyme inducing anti-epileptic drugs. To assess the efficacy of GW572016 when administered daily in appropriate recommended doses to patients with recurrent GBM. 

Participation: Participation in this study is restricted to invited centres. 

Primary Publication Show

Other Publications Show

Inventory
Hide Tissue Samples
Disease Site Trial Code Patients Accrued Patients - Blocks Patients - Slides Patients - Blocks and/or Slides
IND I170 24 5 22 22
Hide TMA Samples
(Core size is 0.6 mm)
Disease Site Trial Code Patients Accrued TMA Blocks Patients on TMA Blocks
IND I170 24 0 0
Hide Fluid Samples
Disease Site Trial Code Patients Accrued Patients - Whole Blood Patients - Cellular Component of Blood Patients - DNA extracted from Blood Patients - RNA extracted from Blood Patients - Plasma Patients - Serum Patients - Urine Patients - Buccal
IND I170 24 0 0 0 0 0 0 0 0